MHRA issues Medicine Defect Information about Aripiprazole

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has been informed by Mylan UK Healthcare Ltd that they received a complaint about a crystalline precipitate forming in Aripiprazole 1mg/ml oral solution.

According to the MHRA, the product is not being recalled due to concerns with continuity of supply. However, they advise that when Aripiprazole 1mg/ml oral solution is used it is visually inspected prior to administration to ensure it is clear and free of any precipitates.

Aripiprazole oral solution is indicated for the treatment of schizophrenia in adults and adolescents aged over 15 years. The drug is also used in treating moderate to severe manic episodes in Bipolar I Disorder patients aged 13 and older.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.